Broadly Neutralizing Antibodies for HIV Eradication View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-02-03

AUTHORS

Kathryn E. Stephenson, Dan H. Barouch

ABSTRACT

Passive transfer of antibodies has long been considered a potential treatment modality for infectious diseases, including HIV. Early efforts to use antibodies to suppress HIV replication, however, were largely unsuccessful, as the antibodies that were studied neutralized only a relatively narrow spectrum of viral strains and were not very potent. Recent advances have led to the discovery of a large portfolio of human monoclonal antibodies that are broadly neutralizing across many HIV-1 subtypes and are also substantially more potent. These antibodies target multiple different epitopes on the HIV envelope, thus allowing for the development of antibody combinations. In this review, we discuss the application of broadly neutralizing antibodies (bNAbs) for HIV treatment and HIV eradication strategies. We highlight bNAbs that target key epitopes, such as the CD4 binding site and the V2/V3-glycan-dependent sites, and we discuss several bNAbs that are currently in the clinical development pipeline. More... »

PAGES

31-37

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11904-016-0299-7

DOI

http://dx.doi.org/10.1007/s11904-016-0299-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1005667407

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26841901


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Neutralizing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Viral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Binding Sites", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epitopes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Envelope Protein gp120", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV-1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy, Adoptive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peptide Fragments", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Viral Envelope Proteins", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Ragon Institute of MGH, MIT, and Harvard, Boston, MA USA", 
          "id": "http://www.grid.ac/institutes/grid.461656.6", 
          "name": [
            "Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-1043, 330 Brookline Avenue, Boston, MA 02215 USA", 
            "Ragon Institute of MGH, MIT, and Harvard, Boston, MA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stephenson", 
        "givenName": "Kathryn E.", 
        "id": "sg:person.01251576771.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251576771.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ragon Institute of MGH, MIT, and Harvard, Boston, MA USA", 
          "id": "http://www.grid.ac/institutes/grid.461656.6", 
          "name": [
            "Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-1043, 330 Brookline Avenue, Boston, MA 02215 USA", 
            "Ragon Institute of MGH, MIT, and Harvard, Boston, MA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barouch", 
        "givenName": "Dan H.", 
        "id": "sg:person.0644324362.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644324362.10"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nature13036", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032264965", 
          "https://doi.org/10.1038/nature13036"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature12744", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025637640", 
          "https://doi.org/10.1038/nature12744"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature10696", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016437859", 
          "https://doi.org/10.1038/nature10696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature12746", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029594927", 
          "https://doi.org/10.1038/nature12746"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature10373", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044845665", 
          "https://doi.org/10.1038/nature10373"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm1244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003729367", 
          "https://doi.org/10.1038/nm1244"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature14411", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045337010", 
          "https://doi.org/10.1038/nature14411"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-02-03", 
    "datePublishedReg": "2016-02-03", 
    "description": "Passive transfer of antibodies has long been considered a potential treatment modality for infectious diseases, including HIV. Early efforts to use antibodies to suppress HIV replication, however, were largely unsuccessful, as the antibodies that were studied neutralized only a relatively narrow spectrum of viral strains and were not very potent. Recent advances have led to the discovery of a large portfolio of human monoclonal antibodies that are broadly neutralizing across many HIV-1 subtypes and are also substantially more potent. These antibodies target multiple different epitopes on the HIV envelope, thus allowing for the development of antibody combinations. In this review, we discuss the application of broadly neutralizing antibodies (bNAbs) for HIV treatment and HIV eradication strategies. We highlight bNAbs that target key epitopes, such as the CD4 binding site and the V2/V3-glycan-dependent sites, and we discuss several bNAbs that are currently in the clinical development pipeline. ", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11904-016-0299-7", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1034743", 
        "issn": [
          "1548-3568", 
          "1548-3576"
        ], 
        "name": "Current HIV/AIDS Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "HIV eradication strategies", 
      "HIV-1 subtypes", 
      "potential treatment modality", 
      "human monoclonal antibody", 
      "clinical development pipeline", 
      "HIV eradication", 
      "HIV replication", 
      "HIV treatment", 
      "treatment modalities", 
      "neutralizing antibodies", 
      "HIV envelope", 
      "passive transfer", 
      "antibody combinations", 
      "infectious diseases", 
      "viral strains", 
      "different epitopes", 
      "monoclonal antibodies", 
      "key epitopes", 
      "antibodies", 
      "eradication strategies", 
      "development pipeline", 
      "epitopes", 
      "CD4", 
      "HIV", 
      "bnAbs", 
      "subtypes", 
      "disease", 
      "narrow spectrum", 
      "eradication", 
      "modalities", 
      "treatment", 
      "recent advances", 
      "review", 
      "replication", 
      "sites", 
      "strains", 
      "advances", 
      "combination", 
      "development", 
      "strategies", 
      "discovery", 
      "efforts", 
      "early efforts", 
      "envelope", 
      "transfer", 
      "spectra", 
      "applications", 
      "pipeline", 
      "large portfolio", 
      "portfolio", 
      "multiple different epitopes", 
      "V2/V3-glycan-dependent sites", 
      "V3-glycan-dependent sites"
    ], 
    "name": "Broadly Neutralizing Antibodies for HIV Eradication", 
    "pagination": "31-37", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1005667407"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11904-016-0299-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26841901"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11904-016-0299-7", 
      "https://app.dimensions.ai/details/publication/pub.1005667407"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_709.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11904-016-0299-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11904-016-0299-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11904-016-0299-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11904-016-0299-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11904-016-0299-7'


 

This table displays all metadata directly associated to this object as RDF triples.

203 TRIPLES      22 PREDICATES      99 URIs      83 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11904-016-0299-7 schema:about N1177e33733a949488c77035339b78a6c
2 N2bc9c4321d524c80a6abde5cb8a21104
3 N3887d158fa1943feb1fd3d772e35f917
4 N43ece8d48b844330bd02f6315a9f2265
5 N4e0c04c549d54e11a0a55ab88f70ed40
6 N4ec7ca085ebe4363b81e0f58d205e8bb
7 N4f4d608566b54d9cab42729b445214d2
8 N5412a6af6f614f5ba0eb74d508b6f7fe
9 N5d8b07ef43ab41e7b1caffafb0e4e938
10 N62e3b7edc24b4246b5fe12d26fab8678
11 N8596494408134aaf8e8635cd09172cb6
12 Nd70b7a287f13465085fbce20e635571e
13 anzsrc-for:11
14 anzsrc-for:1103
15 anzsrc-for:1107
16 schema:author Nd178d33693a24de4a3669c3a569e0554
17 schema:citation sg:pub.10.1038/nature10373
18 sg:pub.10.1038/nature10696
19 sg:pub.10.1038/nature12744
20 sg:pub.10.1038/nature12746
21 sg:pub.10.1038/nature13036
22 sg:pub.10.1038/nature14411
23 sg:pub.10.1038/nm1244
24 schema:datePublished 2016-02-03
25 schema:datePublishedReg 2016-02-03
26 schema:description Passive transfer of antibodies has long been considered a potential treatment modality for infectious diseases, including HIV. Early efforts to use antibodies to suppress HIV replication, however, were largely unsuccessful, as the antibodies that were studied neutralized only a relatively narrow spectrum of viral strains and were not very potent. Recent advances have led to the discovery of a large portfolio of human monoclonal antibodies that are broadly neutralizing across many HIV-1 subtypes and are also substantially more potent. These antibodies target multiple different epitopes on the HIV envelope, thus allowing for the development of antibody combinations. In this review, we discuss the application of broadly neutralizing antibodies (bNAbs) for HIV treatment and HIV eradication strategies. We highlight bNAbs that target key epitopes, such as the CD4 binding site and the V2/V3-glycan-dependent sites, and we discuss several bNAbs that are currently in the clinical development pipeline.
27 schema:genre article
28 schema:inLanguage en
29 schema:isAccessibleForFree true
30 schema:isPartOf N47b0e0fa95c549c09bbc7a13bf9840a3
31 Nc6918ce5bec640ebb449dc6451d6961d
32 sg:journal.1034743
33 schema:keywords CD4
34 HIV
35 HIV envelope
36 HIV eradication
37 HIV eradication strategies
38 HIV replication
39 HIV treatment
40 HIV-1 subtypes
41 V2/V3-glycan-dependent sites
42 V3-glycan-dependent sites
43 advances
44 antibodies
45 antibody combinations
46 applications
47 bnAbs
48 clinical development pipeline
49 combination
50 development
51 development pipeline
52 different epitopes
53 discovery
54 disease
55 early efforts
56 efforts
57 envelope
58 epitopes
59 eradication
60 eradication strategies
61 human monoclonal antibody
62 infectious diseases
63 key epitopes
64 large portfolio
65 modalities
66 monoclonal antibodies
67 multiple different epitopes
68 narrow spectrum
69 neutralizing antibodies
70 passive transfer
71 pipeline
72 portfolio
73 potential treatment modality
74 recent advances
75 replication
76 review
77 sites
78 spectra
79 strains
80 strategies
81 subtypes
82 transfer
83 treatment
84 treatment modalities
85 viral strains
86 schema:name Broadly Neutralizing Antibodies for HIV Eradication
87 schema:pagination 31-37
88 schema:productId N40028432676840a8a380a3cacc4fcbe5
89 N7e9e78ac39134f9395ee5ef65c7e4271
90 Nfe899be237d94904b2fc13d0fdb7e278
91 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005667407
92 https://doi.org/10.1007/s11904-016-0299-7
93 schema:sdDatePublished 2022-01-01T18:41
94 schema:sdLicense https://scigraph.springernature.com/explorer/license/
95 schema:sdPublisher N3dd8e7ae46f94742a22d29f6ecb53e7c
96 schema:url https://doi.org/10.1007/s11904-016-0299-7
97 sgo:license sg:explorer/license/
98 sgo:sdDataset articles
99 rdf:type schema:ScholarlyArticle
100 N1177e33733a949488c77035339b78a6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Antibodies, Monoclonal
102 rdf:type schema:DefinedTerm
103 N2bc9c4321d524c80a6abde5cb8a21104 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Epitopes
105 rdf:type schema:DefinedTerm
106 N3887d158fa1943feb1fd3d772e35f917 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Antibodies, Neutralizing
108 rdf:type schema:DefinedTerm
109 N3dd8e7ae46f94742a22d29f6ecb53e7c schema:name Springer Nature - SN SciGraph project
110 rdf:type schema:Organization
111 N40028432676840a8a380a3cacc4fcbe5 schema:name doi
112 schema:value 10.1007/s11904-016-0299-7
113 rdf:type schema:PropertyValue
114 N43ece8d48b844330bd02f6315a9f2265 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Antibodies, Viral
116 rdf:type schema:DefinedTerm
117 N47b0e0fa95c549c09bbc7a13bf9840a3 schema:volumeNumber 13
118 rdf:type schema:PublicationVolume
119 N4e0c04c549d54e11a0a55ab88f70ed40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name HIV-1
121 rdf:type schema:DefinedTerm
122 N4ec7ca085ebe4363b81e0f58d205e8bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name HIV Infections
124 rdf:type schema:DefinedTerm
125 N4f4d608566b54d9cab42729b445214d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Humans
127 rdf:type schema:DefinedTerm
128 N5412a6af6f614f5ba0eb74d508b6f7fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name HIV Envelope Protein gp120
130 rdf:type schema:DefinedTerm
131 N5d8b07ef43ab41e7b1caffafb0e4e938 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Viral Envelope Proteins
133 rdf:type schema:DefinedTerm
134 N62e3b7edc24b4246b5fe12d26fab8678 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Binding Sites
136 rdf:type schema:DefinedTerm
137 N7e9e78ac39134f9395ee5ef65c7e4271 schema:name dimensions_id
138 schema:value pub.1005667407
139 rdf:type schema:PropertyValue
140 N8596494408134aaf8e8635cd09172cb6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Immunotherapy, Adoptive
142 rdf:type schema:DefinedTerm
143 Nc6918ce5bec640ebb449dc6451d6961d schema:issueNumber 1
144 rdf:type schema:PublicationIssue
145 Nd178d33693a24de4a3669c3a569e0554 rdf:first sg:person.01251576771.89
146 rdf:rest Nf8f5ccd1f7854694b4919b494144d434
147 Nd70b7a287f13465085fbce20e635571e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Peptide Fragments
149 rdf:type schema:DefinedTerm
150 Nf8f5ccd1f7854694b4919b494144d434 rdf:first sg:person.0644324362.10
151 rdf:rest rdf:nil
152 Nfe899be237d94904b2fc13d0fdb7e278 schema:name pubmed_id
153 schema:value 26841901
154 rdf:type schema:PropertyValue
155 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
156 schema:name Medical and Health Sciences
157 rdf:type schema:DefinedTerm
158 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
159 schema:name Clinical Sciences
160 rdf:type schema:DefinedTerm
161 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
162 schema:name Immunology
163 rdf:type schema:DefinedTerm
164 sg:journal.1034743 schema:issn 1548-3568
165 1548-3576
166 schema:name Current HIV/AIDS Reports
167 schema:publisher Springer Nature
168 rdf:type schema:Periodical
169 sg:person.01251576771.89 schema:affiliation grid-institutes:grid.461656.6
170 schema:familyName Stephenson
171 schema:givenName Kathryn E.
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251576771.89
173 rdf:type schema:Person
174 sg:person.0644324362.10 schema:affiliation grid-institutes:grid.461656.6
175 schema:familyName Barouch
176 schema:givenName Dan H.
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644324362.10
178 rdf:type schema:Person
179 sg:pub.10.1038/nature10373 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044845665
180 https://doi.org/10.1038/nature10373
181 rdf:type schema:CreativeWork
182 sg:pub.10.1038/nature10696 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016437859
183 https://doi.org/10.1038/nature10696
184 rdf:type schema:CreativeWork
185 sg:pub.10.1038/nature12744 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025637640
186 https://doi.org/10.1038/nature12744
187 rdf:type schema:CreativeWork
188 sg:pub.10.1038/nature12746 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029594927
189 https://doi.org/10.1038/nature12746
190 rdf:type schema:CreativeWork
191 sg:pub.10.1038/nature13036 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032264965
192 https://doi.org/10.1038/nature13036
193 rdf:type schema:CreativeWork
194 sg:pub.10.1038/nature14411 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045337010
195 https://doi.org/10.1038/nature14411
196 rdf:type schema:CreativeWork
197 sg:pub.10.1038/nm1244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003729367
198 https://doi.org/10.1038/nm1244
199 rdf:type schema:CreativeWork
200 grid-institutes:grid.461656.6 schema:alternateName Ragon Institute of MGH, MIT, and Harvard, Boston, MA USA
201 schema:name Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-1043, 330 Brookline Avenue, Boston, MA 02215 USA
202 Ragon Institute of MGH, MIT, and Harvard, Boston, MA USA
203 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...